Don’t miss the latest developments in business and finance.

Outcome of board meeting of Natco Pharma

Image
Capital Market
Last Updated : Sep 02 2022 | 1:16 PM IST

Held on 02 September 2022

The Board of Natco Pharma at its meeting held on 02 September 2022 has approved the following:

To sell the investment of 15% of shareholding in Joint Limited Liability Company (JLLC) Nativita, a Company registered under the Companies Law of the Republic of Belarus for an amount of 3,45,000 Euros to M/s. Pharmasyntez-Nord Joint Stock Company, a legal entity under the laws of the Russian Federation subject to the approval of the Statutory and Regulatory Authorities.

To assign the leasehold land wherein the Company's Pharma Division is situated i.e., Plot No. 19 and Plot No. 18-A situated at Pharma City, SIIDCUL, Selaqui, Tehsil - Vikasnagar, Dehradun, Uttarakhand, India and sell the buildings, plant, machinery and fixtures constructed and/or installed in Plot No. 19 to M/s. Odon Lifesciences for an amount of Rs.15.73 crore which is subject to the approval of State Infrastructure and Industrial Development Corporation of Uttarakhand (SIIDCUL), other Statutory and Regulatory Authorities.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Sep 02 2022 | 12:52 PM IST

Next Story